Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

A Q&A With Lilly Biomedicines President Christi Shaw

May 25 2018

• By Jessica Merrill

Christi Shaw — Lilly Biomedicines President Christi Shaw

Related Content

Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?

May 15 2018

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

May 18 2018

Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee

Apr 24 2018

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

May 12 2018

Related Companies

Eli Lilly and Company

Johnson & Johnson

Novartis AG

Amgen, Inc.

Additional Topics

Leadership Launches Business Strategies Commercial Pricing Debate BioPharmaceutical

More from Leadership

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window